PFS and OS of first- and second-line daratumumab calculated by the models. (A) PFS, (B) OS by the GRIFFIN model, and (C) PFS, and (D) OS by the CASSIOPEIA model. Survival curves are shown from clinical trials; curves marked “estimated” in the key were calculated using the model.